Sitriptylol is a medication specifically designed to treat epilepsy, primarily exerting therapeutic effects through a dual mechanism of action

Drug name

Common name: Stiripentol

Product Name: Diacomit

Other names: DIACOMIT Capsules/Oral Suspension

indication

Used for the treatment of epileptic seizures in patients with Dravet syndrome aged 2 years and above (in combination with chlorpromazine). There is no clinical data support for monotherapy for Dravet syndrome.

Specifications and characteristics

Capsules:

250mg: No.2 pink capsule, printed with "Diacomit" and "250mg"

500mg: White capsule size 0, printed with "Diacomit" and "500mg"

Oral suspension:

250mg/pack or 500mg/pack light pink fruity powder

main ingredients

Active ingredient: Streptopentanol

Accessories: Capsules containing gelatin, magnesium stearate, etc; Suspension containing aspartame (including phenylalanine)

Usage and Dosage

Standard dose: 50mg/kg/day, taken in 2-3 doses (maximum daily dose 3000mg)

Usage:

Capsules: Swallow whole, take with a glass of water during meals

Suspension: Take immediately after mixing 100mL of water, then rinse with 25mL of water

Dose adjustment

1. Missed medication: Take it immediately, skip if it is close to the next medication time

2. Vomiting: No need for supplementation, take the next dose according to the original plan

3. Medication discontinuation: gradual reduction is required (sudden discontinuation may trigger status epilepticus)

Medication precautions

1. Dosage: Must be taken with meals to improve absorption

2. Special treatment:

Capsules should not be opened or chewed

Suspension agent needs to be prepared and used immediately, and cannot be stored

3. Monitoring requirements: Blood routine examination before medication and every 6 months

Medication for special populations

Pregnant women: May cause fetal malformation, need to weigh the pros and cons (pregnancy registration number 1-888-233-2334)

Breastfeeding period: No relevant data available, it is recommended to suspend breastfeeding

Children: Safety not established for children under 2 years old

Liver and kidney dysfunction: Not recommended for moderate to severe patients

adverse reaction

Common (≥ 10%): drowsiness (67%), decreased appetite (45%), ataxia (27%), weight loss (27%)

Serious adverse reactions: neutropenia (13%), thrombocytopenia (13%), QT interval prolongation

contraindication

There are no absolute contraindications, but suspension (containing phenylalanine) is contraindicated for patients with phenylketonuria

Drug interactions

1. Increase concentration: Increase the concentration of chlorpromazine and its metabolites by 2-5 times (reduce by 25%)

2. Taboo combination: Strong CYP1A2/CYP3A4 inducers (such as rifampicin)

3. Caution in combination: CNS inhibitors (aggravating drowsiness)

Storage method

1. Temperature: 20-25 ℃ (allows short-term storage at 15-30 ℃)

2. Environment: Store in the original packaging away from light and moisture

3. Deadline: Do not store for a long time after opening

manufacturer

BIOCODEX, France (1 venue Blaise Pascal, 60000 BEAUVAIS)

Diacomitinformation